Allogene Therapeutics Stock (NASDAQ: ALLO) stock price, news, charts, stock research, profile.
Open | $2.800 |
Close | - |
Volume / Avg. | 1.558M / 2.316M |
Day Range | 2.700 - 2.910 |
52 Wk Range | 2.230 - 6.890 |
Market Cap | $473.757M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 20 |
Short Interest | 27.8% |
Days to Cover | 16.63 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Allogene Therapeutics (NASDAQ: ALLO) through any online brokerage.
Other companies in Allogene Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN) and Celcuity (NASDAQ:CELC).
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by HC Wainwright & Co. on Tuesday, March 19, 2024. The analyst firm set a price target for 10.00 expecting ALLO to rise to within 12 months (a possible 260.36% upside). 23 analyst firms have reported ratings in the last year.
The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $2.775 last updated Today at April 30, 2024 at 3:56 PM EDT.
There are no upcoming dividends for Allogene Therapeutics.
Allogene Therapeutics’s Q1 earnings are confirmed for Tuesday, May 14, 2024.
There is no upcoming split for Allogene Therapeutics.
Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.